4,519 reports of this reaction
13.5% of all OLAPARIB reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for OLAPARIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 4,519 FDA adverse event reports linking OLAPARIB to DEATH. This represents approximately 13.5% of all 33,417 adverse event reports for this drug.
Patients taking OLAPARIB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a frequently reported adverse event for OLAPARIB, accounting for a significant proportion of all reports.
In addition to death, the following adverse reactions have been reported for OLAPARIB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 4,519 FDA reports for OLAPARIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 13.5% of all adverse event reports for OLAPARIB, making it one of the most commonly reported side effect.
If you experience death while taking OLAPARIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.